1. Home
  2. DSY vs CMMB Comparison

DSY vs CMMB Comparison

Compare DSY & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DSY

Big Tree Cloud Holdings Limited Ordinary Shares

HOLD

Current Price

$3.27

Market Cap

15.7M

Sector

N/A

ML Signal

HOLD

CMMB

Chemomab Therapeutics Ltd.

BUY

Current Price

$1.08

Market Cap

8.4M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
DSY
CMMB
Founded
2020
2004
Country
China
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.7M
8.4M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
DSY
CMMB
Price
$3.27
$1.08
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $15.00
AVG Volume (30 Days)
3.8K
★ 102.3K
Earning Date
01-01-0001
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 101.67
EPS
N/A
★ 0.04
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ $16.48
$27.00
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$1.01
52 Week High
$19.90
$3.44

Technical Indicators

Market Signals
Indicator
DSY
CMMB
Relative Strength Index (RSI) 42.47 24.22
Support Level $2.80 N/A
Resistance Level $3.54 $1.89
Average True Range (ATR) 0.10 0.12
MACD 0.00 -0.00
Stochastic Oscillator 44.12 5.36

Price Performance

Historical Comparison
DSY
CMMB

About DSY Big Tree Cloud Holdings Limited Ordinary Shares

Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: